Market Access CTR Summary
|
|
- Primrose Marshall
- 6 years ago
- Views:
Transcription
1 Market Access CTR Summary Study No.: BEL Title: Efficacy of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies (Belimumab IV for Market Access) Rationale: The Phase III belimumab clinical studies HGS1006-C1056 (C1056, BLISS-52) and HGS1006-C1057 (C1057, BLISS-76) were conducted in subjects with active, autoantibody positive systemic lupus erythematosus (SLE). Subpopulations of subjects from these trials with more severe disease were studied further in an effort to see how these individuals respond to belimumab therapy. This information may be of interest to healthcare payers/insurance companies. Phase: III Study Period: The study period covering C1056 and C1057 was 08 February 2007 (1 st subject randomized) to 22 September 2009 (last subject completed 8 week follow-up of 52 week period). This pooled analysis was initiated on 01 July 2009 (analysis plan complete) and completed on 20 August 2010 (study report complete). Study Design: This Market Access report is based on pooled analyses of subpopulations of subjects from the Modified Intent-to-Treat (MITT) Population that was used in the Phase III belimumab clinical studies C1056 and C Week 52 analysis of each of these two studies individually formed the basis for the Biologics License Application (BLA) and Marketing Authorisation Application (MAA) regulatory dossiers submitted in June The analyses for this report were pre-specified and the analysis plan was finalized prior to the database lock of both Phase III studies. The Phase III pivotal safety and efficacy trials were conducted in subjects with active, autoantibody positive SLE. Belimumab was administered in addition to SLE standard of care (SOC) medications. By Week 24 of the trials, restrictions on SOC medications were completely implemented. Centres: Both studies were multicenter. C1056 had 92 centers (41 Asia Pacific; 40 Latin America; 11 Europe). C1057 had 136 centers (62 Europe; 65 North America; 9 Latin America). Indication: SLE Treatment: Subjects were randomly assigned to 1 of 3 treatment groups. The treatment groups consisted of 2 active treatment arms (belimumab 1 and ) and a placebo arm, plus SOC therapy. Belimumab or placebo was administered by intravenous infusion over a 1 hour period. All subjects were to be dosed on Days 0, 14, and 28, then every 28 days. Objectives: Primary objective - Evaluate impact of belimumab treatment on a subpopulation of subjects with severe SLE, including those with critical organ system involvement, to aid payers in making decisions regarding reimbursement and market access. Secondary objective - Evaluate the impact of belimumab treatment on exploratory subpopulations which represent SLE subjects that may be of interest to payers. Primary Outcome/Efficacy Variable: The primary market access endpoint was the response rate at Week 52, consistent with the primary efficacy endpoint for the belimumab Phase III clinical trials. A response was defined as: 4 point reduction from baseline in SELENA SLEDAI 2 score, AND No worsening (increase of AND 0.30 points from baseline) in Physician s Global Assessment (PGA) of Disease, No new BILAG 3 A organ domain score or two new BILAG B organ domain scores compared with baseline at the time of assessment (i.e., at Week 52). 1 Pooled analyses were of efficacy variables only. No safety analyses were conducted. Each study reported safety findings separately. 2 Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 3 British Isles Lupus Assessment Group Page 1
2 Secondary Outcome/Efficacy Variable(s): Percent of subjects with 4 point reduction from baseline in SELENA SLEDAI score at Week 52 Mean change in SF-36 Physical Component Summary (PCS) score at Week 24 Time to first SLE flare after 24 weeks by modified SLE Flare Index (SFI). Statistical Methods: The primary comparisons of interest were the pairwise comparisons of each of the belimumab doses ( and ) plus standard of care versus placebo plus standard of care. All statistical testing was two-sided with significance interpreted at the =0.05 significance level. The primary market access endpoint was analyzed using a logistic regression model. Secondary market access endpoints were analyzed using a logistic regression model, analysis of covariance (ANCOVA), or a Cox proportional hazard model, as appropriate. Study Population: The Primary Market Access (PMA) Population is a subpopulation of the modified Intent-to-Treat (MITT) Population that was used for the belimumab regulatory submissions. The MITT Population had to have a clinical diagnosis of SLE according to the American College of Rheumatology (ACR) criteria and have active SLE disease (defined as a SELENA SLEDAI score of 6 at screening and be positive for autoantibodies, defined as an antinuclear antibodies (ANA) titer of 1:80 and/or anti-dsdna 30 IU/mL at two timepoints prior to randomization). In addition to these criteria, the subpopulation selected for this Market Access report (the PMA Population) had to have renal, neurological, haematological, or cardiovascular/respiratory organ domain involvement (as defined by a BILAG domain score of A, B or C in at least one of the domains) at baseline and at least one of the following: anti-dsdna positive ( 30 IU/mL) at baseline, OR low C3 (<90 mg/dl) and/or C4 (<16 mg/dl) complement relative to the normal range at baseline. MITT population PMA population (% of MITT population) 327 (58.2%) 342 (61.2%) 347 (61.6%) PMA population completed Wk 52, n (% PMA population) 242 (74.0%) 278 (81.3%) 273 (78.7%) Total number PMA population subjects withdrawn, N (%) 85 (26.0%) 64 (18.7%) 74 (21.3%) Withdrawn due to adverse events n (%) 25 (7.6%) 20 (5.8%) 25 (7.2%) Withdrawn due to lack of efficacy n (%) 20 (6.1%) 17 (5.0%) 20 (5.8%) Withdrawn for other reasons n (%) 40 (12.2%) 27 (7.9%) 29 (8.4%) Page 2
3 Demographics PMA population Females: Males 299 (91.4%): 28 (8.6%) 322 (94.2%): 20 (5.8%) 333 (96.0%): 14 (4.0%) Mean Age, years + SD Race 4 White/Caucasian, n (%) 146 (44.6%) 142 (41.5%) 150 (43.2%) European heritage, n (%) 136 (41.7%) 136 (39.8%) 137 (39.5%) Middle Eastern/North African heritage, n (%) 10 (3.1%) 6 (1.8%) 13 (3.7%) Asian, n (%) 83 (25.4%) 83 (24.3%) 98 (28.2%) East Asian heritage, n (%) 53 (16.3%) 52 (15.2%) 58 (16.7%) Southeast Asian heritage, n (%) 19 (5.8%) 15 (4.4%) 25 (7.2%) Central Asian heritage, n (%) (0.3%) South Asian (Indian subcontinent) heritage, n (%) 10 (3.1%) 15 (4.4%) 15 (4.3%) Japanese heritage, n (%) 1 (0.3%) 1 (0,3%) 0 Black/African American, n (%) 33 (10.1%) 28 (8.2%) 34 (9.8%) Alaska Native or American Indian from 64 (19.6%) 89 (26.0%) 65 (18.7%) North/Central/South American, n (%) Native Hawaiian or Other Pacific Islander 1 (0.3%) 0 0 Multiracial, n (%) 1 (0.3%) 2 (0.6%) 2 (0.6%) Hispanic or Latino origin, n (%) 108 (33.0%) 134 (39.2%) 103 (29.7%) Weight in kg, mean + SD PMA Population Baseline Characteristics Disease Activity BILAG Organ Domain Category 5 alphabetic score At least 1A or 2B, n (%) 213 (65.1%) 202 (59.1%) 202 (58.2%) At least 1A, n (%) 53 (16.2%) 61 (17.8%) 44 (12.7%) At least 1A or 1B, n (%) 301 (92.0%) 301 (88.0%) 317 (91.4%) BILAG Category 3 by Organ Domain Renal A - n (%)/B - n(%)/c - n (%) A 1 (0.3%) B 46 (14.1%) C -137 (41.9%) Neurological A - n (%)/B - n(%)/c - n (%) A 0 B 3 (0.9%) C 40 (12.2%) Hematology A - n (%)/B - n(%)/c - n (%) A 1 (0.3%) B 78 (23.9%) C 123 (37.6%) Cardiovascular & Respiratory A - n (%)/B - n(%)/c - n (%) A 3 (0.9%) B 14 (4.3%) C 56 (17.1%) A -6 (1.8%) B 49 (14.3%) C 126 (36.8%) B 4 (1.2%) C 45 (13.2%) B 88 (25.7%) C 122 (35.7%) A 5 (1.5%) B 11 (3.2%) C 53 (15.5%) B 50 (14.4%) C 128 (36.9%) A 1 (0.3%) B 4 (1.2%) C 56 (16.1%) A 3 (0.9%) B 79 (22.8%) C 141 (40.6%) B 15 (4.3%) C 58 (16.7%) SELENA SLEDAI Score Mean + SD < 9, n (%) 116 (35.5%) 140 (40.9%) 145 (41.8%) >10, n (%) 211 (64.5%) 202 (59.1%) 202 (58.2%) PGA Score Mean + SD Subjects with more than one racial sub-category were counted in each sub-category 5 BILAG Organ Domain Categories: A = requires disease modifying treatment, B= mild reversible problems requiring only symptomatic therapy, C= stable mild disease, D= previously affected but currently inactive, E=system never involved (Note Categories D and E assessed but not included here) Page 3
4 PMA Population Baseline Characteristics, contd. Disease Activity, contd. SLE Flare Index At least 1 flare 6, n (%) 86 (26.3%) 68 (19.9%) 70 (20.2%) Proteinuria level (g/24 hr) Mean + SD Serological Activity ANA positive (> 80 titer), n (%) 304 (93.0%) 329 (96.2%) 321 (92.5%) Anti-dsDNA positive (> 30 IU/mL), n (%) 292 (89.3%) 308 (90.1%) 306 (88.2%) Low C3 (<90 mg/dl), n (%) 188 (57.5%) 199 (58.2%) 214 (61.7%) Low C4 (<16 mg/dl), n (%) 229 (70.0%) 246 (71.9%) 252 (72.6%) Primary Efficacy Results: Response Rate at Week 52 Response, n (%) 110 (33.6%) 157 (45.9%) 172 (49.6%) Observed difference vs. (%) % 15.9% Odds Ratio (95% Confidence Interval [CI]) 7 vs (1.3, 2.5) 2.2 (1.6, 3.1) p-value < Odds ratio (95% CI) and p-value were from logistic regression for the comparison between each belimumab dose and placebo with covariates, including baseline SELENA SLEDAI (< 9 vs > 10), baseline proteinuria level (< 2 g/24 h vs > 2 g/24 h equivalent), race (African descent or indigenous-american descent vs. other) and study (HGS1006-C1056 vs. HGS1006-C1057) Secondary Outcome Variable(s): Major Secondary: Percent of subjects with 4 point reduction from baseline in SELENA SLEDAI score at Week 52 Response, n (%) 117 (35.8%) 161 (47.1%) 176 (50.7%) Observed difference vs. (%) % 14.9% Odds Ratio (95% CI) 8 vs (1.3, 2.4) 2.1 (1.5, 2.9) 8 Odds ratio (95% CI) was from logistic regression for the comparison between each belimumab dose and placebo with covariates, including baseline SELENA SLEDAI (< 9 vs > 10), baseline proteinuria level (< 2 g/24 h vs > 2 g/24 h equivalent), race (African descent or indigenous-american descent vs. other) and study (HGS1006-C1056 vs. HGS1006-C1057) 6 Flares occurring between screening and randomization; maximum of 35 days Page 4
5 Secondary Outcome Variable(s), contd. Major Secondary: Mean change in SF-36 Health Survey PCS score from Baseline at Week 24 (Last Observation Carried Forward) N Mean + SE Median (Min, Max) 3.06 (-27.48, 23.88) 3.00 (-22.72, 33.80) 3.24 (-24.41, 30.24) Least Square Mean (LSM) + SE Treatment differences (95% CI) 9 vs placebo (-0.36, 1.76) 0.60 (-0.45, 1.65) 9 All statistics, including the difference in LSM, were from ANCOVA model for the comparison between each belimumab dose and placebo, adjusted for baseline PCS score, baseline SELENA SLEDAI (< 9 vs > 10), baseline proteinuria level (< 2 g/24 h vs > 2 g/24 h equivalent), race (African descent or indigenous-american descent vs. other) and study (HGS1006-C1056 vs. HGS1006-C1057) as covariates. Major Secondary: Time to first SLE flare after 24 weeks by modified SLE flare index n (%) (72.2) 169 (55.4) 186 (60.0) Median days (Min, Max) 93 (1, 218) 149 (1, 207) 112 (2, 204) Hazard ratio (95% CI) vs (0.54, 0.81) 0.74 (0.60, 0.90) 10 Number (%) of subjects with a flare between Week 24 - Week 52 among subjects with at least 1 visit after Week From Cox proportional hazards model for the comparison between each belimumab dose and placebo, adjusted for baseline SELENA SLEDAI score (< 9 vs > 10), baseline proteinuria level (< 2 g/24 h vs > 2 g/24 h equivalent), race (African descent or indigenous-american descent vs. other) and study (HGS1006-C1056 vs. HGS1006-C1057) Conclusion: The Primary Market Access (PMA) Population is a subpopulation of the modified Intent-to-Treat (MITT) Population that was used for the belimumab regulatory submissions. The MITT Population had a clinical diagnosis of SLE according to the American College of Rheumatology (ACR) criteria and active SLE disease (screening SELENA SLEDAI score of 6 and autoantibody positive [antinuclear antibody (ANA) titer of 1:80 and/or anti-dsdna 30 IU/mL at two timepoints prior to randomization]). In addition to these criteria, the PMA Population had renal, neurological, haematological, or cardiovascular/respiratory organ domain involvement (BILAG domain score of A, B or C in at least one of the domains) at baseline and at least one of the following: anti-dsdna positive ( 30 IU/mL) at baseline, OR low C3 (<90 mg/dl) and/or C4 (<16 mg/dl) complement relative to the normal range at baseline With respect to the findings summarized above for the PMA population: Belimumab demonstrated substantial evidence of efficacy. Belimumab 1 and (plus standard of care) achieved a significantly greater response (primary endpoint) compared with placebo (plus standard of care) at Week 52. A significantly greater percentage of subjects treated with belimumab had a 4 point reduction in SELENA SLEDAI score over baseline compared with placebo at Week 52. This is clinically beneficial since a 4 point reduction in SELENA SLEDAI score represents elimination of a sign of symptom of SLE and/or normalization of a clinically important laboratory abnormality. Significant improvements in SF-36 PCS score were not achieved at Week 24 for either belimumab dose compared with placebo. Belimumab had significant beneficial effects on delaying time to first SLE flare after 24 weeks by the modified SLE flare index compared with placebo. Time to SLE flare is an important surrogate marker for SLE disease control. Page 5
Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab
(2016) 25, 346 354 http://lup.sagepub.com PAPER Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab DA Roth 1, A Thompson 2, Y Tang 2*, AE
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBelimumab for the treatment of autoantibody-positive systemic lupus erythematosus.
Belimumab for the treatment of autoantibodypositive systemic lupus erythematosus. ERG REPORT: ERRATA SHEET Page / location Original Change / Replacement Pg 13 para 3, last line P = 0.027 P = 0.0207 Pg
More informationENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. José María Pego Reigosa
ENFERMEDADES AUTOINMUNES SISTÉMICAS Dr. José María Pego Reigosa ABSTRACT NUMBER: 2754 Comparison of Individually Tailored vs Systematic Rituximab Regimens to Maintain ANCA-Associated Vasculitis Remissions:
More informationTechnology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta397
Belimumab for treating active autoantibody-positive systemic lupus erythematosus Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta397 NICE 2018. All rights reserved. Subject
More informationCorporate Presentation January 2013
NASDAQ: ANTH Corporate Presentation January 2013 1 Forward Looking Statements This presentation contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationA 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus
(2018) 27, 1489 1498 journals.sagepub.com/home/lup PAPER of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus A Doria 1, D Bass 2, A Schwarting 3,4, A Hammer
More information* Autoantibody positive (i.e. antinuclear antibody or ANA titre 1:80 or anti-double stranded (ds) DNA antibody 30 IU/mL)
Benlysta (belimumab) Policy Number: 5.02.509 Last Review: 05/2018 Origination: 06/2011 Next Review: 05/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Benlysta
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationBelimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
ARD Online First, published on April 5, 2012 as 10.1136/annrheumdis-2011-200937 1 Unit for Clinical Therapy Research, Infl ammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden 2 Division
More informationEfficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study.
1. Title Efficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study. 2. Background Systemic Lupus Erythematosus (SLE) is a chronic, autoimmune and
More informationProduct: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1
Date: 02 April 2014 Page 1. 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Omecamtiv mecarbil injection Name of Active Ingredient: Omecamtiv mecarbil (AMG 423) Title of Study: A double-blind,
More informationCommittee Approval Date: May 9, 2014 Next Review Date: May 2015
Medication Policy Manual Policy No: dru248 Topic: Benlysta, belimumab Date of Origin: May 13, 2011 Committee Approval Date: May 9, 2014 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More information2.0 Synopsis. Adalimumab M Clinical Study Report R&D/04/900. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2. Synopsis Abbott Laboratories Name of Study Drug: Name of Active Ingredient: Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Phase
More informationNew Drug Evaluation: Belimumab Injection, Intravenous and Subcutaneous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNew Drug Evaluation: Belimumab Injection, Intravenous and Subcutaneous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTreatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBENLYSTA PRODUCT INFORMATION
BENLYSTA PRODUCT INFORMATION NAME OF THE MEDICINE The active ingredient of BENLYSTA is belimumab (rmc). DESCRIPTION Belimumab is a fully human IgG1λ monoclonal antibody specific for soluble human B Lymphocyte
More informationStudy Population: 12 years and older A EF Calcipotriene Foam, 0.005%
Study No.: CAL.203 Title: A Randomized, Open-Label Study to Assess the Bioavailability of Emulsion Formulation Foam, 0.005%, and Dovonex, 0.005%, in Patients with Mild to Moderate Plaque-Type Psoriasis
More informationEXTENDED REPORT. Clinical and epidemiological research
1 Allegheny Singer Research Institute, West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, Pennsylvania, USA 2 Instituto Nacional de Ciencias Medicas y Nutricion Salvador
More informationDemographics and Health Data
Demographics and Health Data Information for Local Planners City of Lakewood, WA Demographic Characteristics Environmental Health Division 3629 South D Street, Tacoma, WA 98418 (253) 798-6470 Table 1 presents
More informationSYNOPSIS. Clinical Study Report IM Double-blind Period
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority
More informationBelimumab: Present and future
Mini Review imedpub Journals http://www.imedpub.com Journal of Autoimmune Disorders Belimumab: Present and future CD Tripathi and Preeta Kaur Chugh Abstract Belimumab, a B lymphocyte stimulator (BLyS)
More informationI.V. CR845 Adaptive Phase 2/3 Post Operative Pain Study Results
I.V. CR845 Adaptive Phase 2/3 Post Operative Pain Study Results A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study Evaluating the Analgesic Efficacy and Safety of I.V. CR845
More informationResearch Article Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus
Hindawi Immunology Research Volume 217, Article ID 17292, pages https://doi.org/.11/217/17292 Research Article Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring
More informationGSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBenlysta (belimumab) Prior Authorization Criteria Program Summary
Benlysta (belimumab) Prior Authorization Criteria Program Summary This prior authorization applies to Commercial, NetResults A series, NetResults F series and Health Insurance Marketplace formularies.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTreatment B: FF (400 µg) and UMEC (250 µg)/vi(100 µg) The indicated dose is the total of four inhalations via the dry powder inhaler.
GSK Medicine:GSK573719 (Umeclidinium)+ GW6424 (Vilanterol) + GW685698 (Fluticasone furoate) Study Number: 200587 Title: An open label, randomised, four-period crossover, single dose study in healthy volunteers
More informationWhich outcome measures in SLE clinical trials best reflect medical judgment?
To cite: Thanou A, Chakravarty E, James JA, et al. Which outcome measures in SLE clinical trials best reflect medical judgment? Lupus Science & Medicine 2014;1:e000005. doi:10.1136/lupus-2013-000005 Received
More informationBaseline Predictors of Systemic Lupus Erythematosus Flares
ARTHRITIS & RHEUMATISM Vol. 65, No. 8, August 2013, pp 2143 2153 DOI 10.1002/art.37995 2013, American College of Rheumatology Baseline Predictors of Systemic Lupus Erythematosus Flares Data From the Combined
More informationBelimumab for the treatment of autoantibody-active systemic lupus erythematosus
National Institute for Health and Clinical Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Belimumab for the treatment of autoantibody-active systemic lupus erythematosus Response
More informationFinal Clinical Study Report. to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI463110
BMS-475 AI463 Name of Sponsor/Company: Bristol-Myers Squibb Individual Study Table Referring to the Dossier For National Authority Use Only) Name of Finished Product: Baraclude Name of Active Ingredient:
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationDemographics and Health Data
Demographics and Health Data Information for Local Planners City of Puyallup, WA Demographic Characteristics Environmental Health Division 3629 South D Street, Tacoma, WA 98418 (253) 798-6470 Table 1 presents
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Belimumab Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 11/15/2017 Next
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationDevelopment of SLE among Possible SLE Patients Seen in Consultation: Long-Term Follow-Up. Disclosures. Background. Evidence-Based Medicine.
Development of SLE among Patients Seen in Consultation: Long-Term Follow-Up Abstract # 1699 May Al Daabil, MD Bonnie L. Bermas, MD Alexander Fine Hsun Tsao Patricia Ho Joseph F. Merola, MD Peter H. Schur,
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCervical Cancer Screening and Prevention in Latinas. Sandra Torrente, MD, MSc Kenneth Grullon, MD
ç Cervical Cancer Screening and Prevention in Latinas Sandra Torrente, MD, MSc Kenneth Grullon, MD Objectives Cervical cancer epidemiology Cervical cancer screening rates locally Health Disparities of
More informationPersistent disease activity may have significant implications for your SLE patients life journey. 1,2
Persistent disease activity may have significant implications for your SLE patients life journey. 1,2 Is it time to increase the focus on disease activity reduction? BENLYSTA (belimumab) is indicated as
More informationGuideline on clinical investigation of medicinal products for the treatment of systemic lupus erythematosus and lupus nephritis
26 February 2015 EMA/CHMP/51230/2013 corr 1 Committee for Medicinal Products for Human use (CHMP) Guideline on clinical investigation of medicinal products for the treatment of systemic lupus erythematosus
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationS^t _j4 A-N.1^.^ A _ WE 2
S^t _j4 A-N.1^.^ A _ WE 2 Name of Sponsor: Amgen Inc. Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to RANKL Title of Study: A Randomized Study
More informationCorrelation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies
Original Article Correlation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies Col K Narayanan *, Col V Marwaha +, Col K Shanmuganandan #, Gp Capt S Shankar
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationLupus: Patient Voices. Report Overview March 6, 2018
Lupus: Patient Voices Report Overview March 6, 2018 Welcome Kathleen Arntsen, Lupus and Allied Diseases Association Sandra Raymond, Lupus Foundation of America Diane Gross, Lupus Research Alliance 2 Goals
More informationWellness Coaching for People with Prediabetes
Wellness Coaching for People with Prediabetes PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY Volume 12, E207 NOVEMBER 2015 ORIGINAL RESEARCH Wellness Coaching for People With Prediabetes: A Randomized Encouragement
More informationChan HLY, Chan CK, Hui AJ, et al. Tenofovir Disoproxil Fumarate in Chronic HBV Infected Patients with Normal ALT and High HBV DNA Levels
Online supplement to: Chan HLY, Chan CK, Hui AJ, et al. Tenofovir Disoproxil Fumarate in Chronic HBV Infected Patients with Normal ALT and High HBV DNA Levels Supplementary Figure 1. CONSORT disposition
More informationWe have continued over the past year with the second wave of follow-up assessments, and remain slightly ahead of our projected recruitment numbers.
Progress Report A. Specific Aims The specific aims of the study remain as they were presented in the proposal. B. Studies and Results The study protocol remains unchanged from the original proposal. During
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating
More informationONE of the following:
Medical Coverage Policy Belimumab (Benlysta) EFFECTIVE DATE: 01 01 2012 POLICY LAST UPDATED: 11 21 2017 OVERVIEW Belimumab (Benlysta ) is indicated for the treatment of adult patients with active, autoantibody-positive,
More informationIssues in Women & Minority Health
Issues in Women & Minority Health Dr. Dawn Upchurch Professor Department of Community Health Sciences PH 150 Dr. Upchurch 1 Overview of Session HP 2010 Model: Determinants of Health Review of HP 2010 Goals
More informationENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. J. María Pego Reigosa
ENFERMEDADES AUTOINMUNES SISTÉMICAS Dr. J. María Pego Reigosa ABSTRACT NUMBER: 888 PHASE 3 TRIAL RESULTS WITH BLISIBIMOD, A SELECTIVE INHIBITOR OF B-CELL ACTIVATING FACTOR, IN SUBJECTS WITH MODERATE-TO-SEVERE
More informationObjective. To assess the efficacy/safety of the B lymphocyte stimulator inhibitor belimumab plus standard therapy compared with placebo plus standard
ARTHRITIS & RHEUMATISM Vol. 63, No. 12, December 2011, pp 3918 3930 DOI 10.1002/art.30613 2011, American College of Rheumatology A Phase III, Randomized, Placebo-Controlled Study of Belimumab, a Monoclonal
More informationEvaluation of Asthma Management in Middle EAst North Africa Adult population
STUDY REPORT SUMMARY Evaluation of Asthma Management in Middle EAst North Africa Adult population Descriptive study on the management of asthma in an asthmatic Middle East Africa adult population Background/Rationale:
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23137E1 Title A
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSynopsis (C0743T10) CNTO 1275 Module 5.3 C0743T10. Associated with Module 5.3 of the Dossier
Module 5.3 Protocol: EudraCT No.: 2005-003525-92 Title of the study: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered
More informationSignificance of Anti-C1q Antibodies in Patients with Systemic Lupus Erythematosus as A Marker of Disease Activity and Lupus Nephritis
THE EGYPTIAN JOURNAL OF IMMUNOLOGY Vol. 23 (1), 2016 Page: 00-00 Significance of Anti-C1q Antibodies in Patients with Systemic Lupus Erythematosus as A Marker of Disease Activity and Lupus Nephritis 1
More informationSoliris in NMOSD Phase 3 PREVENT Study Topline Results September 24, 2018
Soliris in NMOSD Phase 3 PREVENT Study Topline Results September 24, 2018 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationSynopsis (C0168T37 ACT 1)
() Module 5.3 Protocol: CR004777 EudraCT No.: Not Applicable Title of the study: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients with
More information2.0 Synopsis. Adalimumab DE019 OLE (5-year) Clinical Study Report Amendment 1 R&D/06/095. (For National Authority Use Only)
2.0 Synopsis Abbott Laboratories Name of Study Drug: Humira Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationAlcohol use and binge drinking among Hispanic/Latino subculture youth, and the differences in the affect of acculturation
Alcohol use and binge drinking among Hispanic/Latino subculture youth, and the differences in the affect of acculturation Hal Johnson, MPH Florida Substance Abuse Program Office and the FSU Florida Center
More informationSynopsis (C0524T12 GO LIVE)
Protocol: EudraCT No.: 2005-003232-21 Title of the study: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFα Monoclonal Antibody, Administered Intravenously,
More informationAssociations between SLE and spontaneous IFN-g release. Jenna Thomason, MD, MPH Grant Hughes, MD April 29, 2017
Associations between SLE and spontaneous IFN-g release Jenna Thomason, MD, MPH Grant Hughes, MD April 29, 2017 None Disclosures Outline Background Methods Preliminary results Conclusions March, 1980 IFN-g
More informationEVALUATION OF USE OF BELIMUMAB IN CLINICAL PRACTICE SETTINGS PATIENT CASE RECORD FORM PHASE II, MONTH PATIENT FOLLOW-UP
EVALUATION OF USE OF BELIMUMAB IN CLINICAL PRACTICE SETTINGS PATIENT CASE RECORD FORM PHASE II, 18-24 MONTH PATIENT FOLLOW-UP NOTE: Important Definition of Study Treatment Period Please provide patient
More informationSupport for Acetaminophen 1000 mg Over-the-Counter Dose:
Support for Acetaminophen 1000 mg Over-the-Counter Dose: The Dental Impaction Pain Model and Efficacy and Safety Results from McNeil Randomized, Double-Blind, Single-Dose Study of Acetaminophen 1000 mg,
More informationIndividual Study Table Referring to Part of Dossier: Use Only) Name of Study Drug:
2.0 Synopsis AbbVie Inc. Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Adalimumab (Humira ) Page: Name of Active Ingredient: Adalimumab
More informationSupplemental Table 1: Moderate and severe definitions of Celiac Disease Symptom Diary
Supplemental Table 1: Moderate and severe definitions of Celiac Disease Symptom Diary symptoms CDSD Symptom Diarrhea Constipation Abdominal Pain Bloating Nausea Tiredness Moderate Once or twice between
More informationPlease answer the following questions by circling the best response, or by filling in the blank.
1 Please answer the following questions by circling the best response, or by filling in the blank. Demographics Age: Gender: a. Male b. Female Race: a. White d. American Indian/Alaskan Native b. Black
More informationPhase 3c Topline Results. Page 1
Phase 3c Topline Results Page 1 Important Information Any statements in this presentation about future expectations, plans and prospects for the Company including the development and regulatory status
More informationREVANESSE VERSA PROFESSIONAL DIRECTIONS FOR USE
REVANESSE VERSA PROFESSIONAL DIRECTIONS FOR USE Caution: Federal Law restricts this device to sale by, or on the order of, a physician or properly licensed practitioner. DESCRIPTION Revanesse Versa should
More informationThe Epidemiology of Tuberculosis in Minnesota,
The Epidemiology of Tuberculosis in Minnesota, 2011 2015 Minnesota Department of Health Tuberculosis Prevention and Control Program (651) 201-5414 Tuberculosis surveillance data for Minnesota are available
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationNIH Public Access Author Manuscript Arthritis Rheum. Author manuscript; available in PMC 2010 September 15.
NIH Public Access Author Manuscript Published in final edited form as: Arthritis Rheum. 2009 September 15; 61(9): 1143 1151. doi:10.1002/art.24698. Novel Evidence-Based Systemic Lupus Erythematosus Responder
More informationOncology Clinical Research & Race: Statistical Principles
Oncology Clinical Research & Race: Statistical Principles Daniel Sargent, PhD ALLIANCE Group Statistician November 2014 The Literary Digest predicted Alf Landon would win the presidency in 1936 1936 PRESIDENTIAL
More informationFederation of State Boards of Physical Therapy Minimum Data Set Questionnaire
Federation of State Boards of Physical Therapy Minimum Data Set Questionnaire Purpose: Understanding the current United States Health Workforce enables Federal and State Governments and Health Professional
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAllergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel
Peripheral Neuropathy Design, Dose Ranging Study of the Safety and Efficacy of AGN 203818 in Patients with Painful Diabetic 203818-004. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple
More information2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Zemplar Injection Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Item of the Submission: Volume: Page: (For National Authority
More informationSummary of Risk Minimization Measures
Table 6.1.4-1: Summary of Risk Minimization Measures Safety Concern Vaccination Hepatic and renal impairment Combination therapy Elderly Routine Risk Minimization Measures Specific subsection on vaccination
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: belimumab_benlysta 6/2011 2/2018 2/2019 3/2018 Description of Procedure or Service Belimumab (Benlysta) is
More informationGSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and nonapproved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationProduct: Denosumab (AMG 162) Synopsis Clinical Study Report: Date: 29 July 2008
Name of Sponsor: Amgen Inc., Thousand Oaks, CA Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb ligand
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTaming the wolf: Treating to target, treating to remission new strategies for SLE
Taming the wolf: Treating to target, treating to remission new strategies for SLE Ronald van Vollenhoven Seattle, April 28, 2017 Disclosures Research support, consultancy: Abbott (AbbVie), Biotest, BMS,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information